Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.

9 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration.

18 Nov 2013

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.

18 Nov 2013

Study evaluates sexual well-being in SCT survivors using sexual function assessment tools

New research ties preparative procedures and complications associated with blood or bone marrow transplantation (stem cell transplantation, SCT) with diminished sexual health in both men and women who have undergone the lifesaving procedure. Study data, published online today in Blood, the Journal of the American Society of Hematology, confirm chronic graft-versus-host disease, a serious complication that occurs when donor cells attack the recipient's cells, as a potential source of sexual dysfunction and are the first to demonstrate an association between total body irradiation and sexual dysfunction in men.

25 Oct 2013

Scientists to combine NK cell therapy with immunocytokine to target childhood cancer

Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.

11 Oct 2013

New method for improving cord blood transplant success

Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation.

9 Oct 2013

Kiadis five-year follow-up phase I/II clinical study confirms long-term safety, efficacy of ATIR

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that the five-year follow-up of patients with high-risk malignancies from its Phase I/II clinical study confirms long-term safety and efficacy of ATIR™ over a broad dose range.

12 Sep 2013

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

Patients with advanced chronic lymphocytic leukemia often receive donor transplants that effectively "reboot" their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there is a high rate of relapse in these patients, and the transplanted immune cells may also harm normal tissues, causing graft-versus-host disease.

7 Aug 2013

Certain gastrointestinal types of GVHD are associated with worsened quality of life and death

Joseph Pidala, M.D., M.S., assistant member of the Blood and Bone Marrow Transplant and Immunology programs at Moffitt Cancer Center, and colleagues from the Chronic Graft-Versus-Host Disease Consortium have determined that certain gastrointestinal and liver-related types of chronic graft-versus-host disease (GVHD) are associated with worsened quality of life and death.

18 Jun 2013

Scientists study repeating patterns in nature to better understand role of immune system in cancer

Can the patterns in tree branches or the meandering bends in a river provide clues that could lead to better cancer therapies? According to a new study from Virginia Commonwealth University Massey Cancer Center, these self-similar, repeating patterns in nature known as fractals help scientists better understand how the immune system is organized and may one day be used to help improve stem cell transplant outcomes in leukemia patients by predicting the probability of transplant complications.

2 May 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

Doctors give new hope for leukemia patients

Leukemia patients receive a bone marrow transplant, which allows them to build a "new" immune system. However, this immune system not only attacks cancer cells but healthy tissue too.

3 Apr 2013

Investigators examine effectiveness of probiotics for cancer treatment

One may not think of probiotics -- like those found in yogurt that promote good digestive health -- as a weapon used in the fight against cancer. But that is the focus of investigators at The Cancer Institute of New Jersey, who are examining the effectiveness of probiotics as they relate to the outcomes of bone marrow transplant for patients with blood cancers.

21 Mar 2013

Mesenchymal stem cells safe, effective for treating poor graft function: Study

When a research team in China evaluated the efficacy and safety of using mesenchymal stem cells expanded from the bone marrow of non-self-donors to treat patients experiencing poor graft function after receiving transplants of non-self-donated blood stem cells (allo-HSCT), they found that the mesenchymal stem cells were both safe and effective for treating primary and secondary PGF.

19 Mar 2013

Umbilical cord blood stem cell transplants may be an effective alternative to treat Hurler's syndrome

Transplants of blood-forming stem cells from umbilical cord blood may be an effective alternative to transplants of matched donor bone marrow stem cells to treat children with a rare, debilitating disease known as Hurler's syndrome (HS), according to results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

17 Mar 2013

USF, Saneron receive patent for transplantation method using umbilical cord blood cells

Researchers at Saneron CCEL Therapeutics and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as Parkinson's disease, Huntington's disease, multiple sclerosis, Alzheimer's disease as well as brain and spinal cord injury.

7 Mar 2013

Global inhibition of all Notch signals would not be safe after bone marrow transplantation

Bone marrow transplant is a key treatment for patients with leukemia, lymphoma, multiple myeloma and other blood disorders. University of Michigan researchers have discovered that inhibiting a signaling pathway in some of the transplanted cells could prevent the most serious potential complications of the procedure, a conflict between the transplanted cells and the recipient's own tissue called graft-versus-host disease.

2 Mar 2013

EMA designates Osiris as Orphan Drug title holder for Prochymal

Osiris Therapeutics, Inc., the leading stem cell company developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that the European Medicines Agency (EMA) has designated Osiris as the Orphan Drug title holder for Prochymal (remestemcel-L).

19 Feb 2013

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Merck announces approval of NOXAFIL delayed-release tablets by FDA

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Study evaluates sexual well-being in SCT survivors using sexual function assessment tools

Scientists to combine NK cell therapy with immunocytokine to target childhood cancer

New method for improving cord blood transplant success

Kiadis five-year follow-up phase I/II clinical study confirms long-term safety, efficacy of ATIR

Autologous tumor cell vaccination: An effective strategy to advance long-term leukemia control

Certain gastrointestinal types of GVHD are associated with worsened quality of life and death

Scientists study repeating patterns in nature to better understand role of immune system in cancer

FDA accepts Merck's NDA for NOXAFIL tablets

Doctors give new hope for leukemia patients

Investigators examine effectiveness of probiotics for cancer treatment

Mesenchymal stem cells safe, effective for treating poor graft function: Study

Umbilical cord blood stem cell transplants may be an effective alternative to treat Hurler's syndrome

USF, Saneron receive patent for transplantation method using umbilical cord blood cells

Global inhibition of all Notch signals would not be safe after bone marrow transplantation

EMA designates Osiris as Orphan Drug title holder for Prochymal

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in